Show simple item record

dc.contributor.authorRyder, Stephen D.
dc.date.accessioned2024-01-24T15:13:36Z
dc.date.available2024-01-24T15:13:36Z
dc.date.issued2023
dc.identifier.citationKutmutia, R., Tittanegro, T., China, L., Forrest, E., Kallis, Y., Ryder, S.D., Wright, G., Freemantle, N. and O'Brien, A. (2023) 'Evaluating the role of antibiotics in patients admitted to hospital With decompensated cirrhosis: Lessons from the ATTIRE trial', The American Journal of Gastroenterology, 118(1), pp. 105-113. doi: 10.14309/ajg.0000000000001937 https://doi.org/10.14309/ajg.0000000000001937.en_US
dc.identifier.issn1572-0241
dc.identifier.urihttp://hdl.handle.net/20.500.12904/18161
dc.description.abstractINTRODUCTION: Hospital-acquired infections (HAI) are common in cirrhosis with antibiotics frequently used to prevent infections, but their efficacy for this role is unknown. To investigate this, we used Albumin to Prevent Infection in Chronic Liver Failure (ATTIRE) data to evaluate whether antibiotic use in patients without infection prevented HAI. METHOD(S): In ATTIRE patients without infection at baseline grouped by antibiotic prescription or not, we studied HAI during trial treatment period and mortality, with propensity score matching to account for differences in disease severity. RESULT(S): Two hundred three of 408 patients prescribed antibiotics at enrollment did not have infection and they were more unwell than noninfected patients not given antibiotics. There were no differences in subsequent HAI comparing antibiotic treated (39/203, 19.2%) to nonantibiotic treated (73/360, 20.3%; P = 0.83). Twenty-eight-day mortality was higher in antibiotic-treated patients ( P = 0.004) likely reflecting increased disease severity. Matching groups using propensity scoring revealed no differences in HAI or mortality. In noninfected patients at enrollment treated with/without rifaximin, there were no differences in HAI ( P = 0.16) or mortality, confirmed with propensity matching. Patients given long-term antibiotic prophylaxis at discharge had no differences in 6-month mortality compared with nonantibiotic patients, although antibiotic-treated patients had more infections at trial entry, with numbers too small for matching. DISCUSSION: Half of antibiotics at study entry were given to patients without an infection diagnosis which did not reduce the overall risk of HAI or improve mortality. This supports prompt de-escalation or discontinuation of antibiotics guided by culture sensitivities at 24-48 hours after commencement if no infection and the patient is improving.Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
dc.description.urihttps://doi.org/10.14309/ajg.0000000000001937en_US
dc.language.isoenen_US
dc.subjectLiver cirrhosisen_US
dc.subjectAntibiotic prophylaxisen_US
dc.subjectAlbuminen_US
dc.titleEvaluating the role of antibiotics in patients admitted to hospital With decompensated cirrhosis: Lessons from the ATTIRE trialen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.14309/ajg.0000000000001937en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.dateFCD2024-01-24T15:13:37Z
refterms.versionFCDVoR
refterms.dateFOA2024-01-24T15:13:37Z
refterms.panelUnspecifieden_US
html.description.abstractINTRODUCTION: Hospital-acquired infections (HAI) are common in cirrhosis with antibiotics frequently used to prevent infections, but their efficacy for this role is unknown. To investigate this, we used Albumin to Prevent Infection in Chronic Liver Failure (ATTIRE) data to evaluate whether antibiotic use in patients without infection prevented HAI. METHOD(S): In ATTIRE patients without infection at baseline grouped by antibiotic prescription or not, we studied HAI during trial treatment period and mortality, with propensity score matching to account for differences in disease severity. RESULT(S): Two hundred three of 408 patients prescribed antibiotics at enrollment did not have infection and they were more unwell than noninfected patients not given antibiotics. There were no differences in subsequent HAI comparing antibiotic treated (39/203, 19.2%) to nonantibiotic treated (73/360, 20.3%; P = 0.83). Twenty-eight-day mortality was higher in antibiotic-treated patients ( P = 0.004) likely reflecting increased disease severity. Matching groups using propensity scoring revealed no differences in HAI or mortality. In noninfected patients at enrollment treated with/without rifaximin, there were no differences in HAI ( P = 0.16) or mortality, confirmed with propensity matching. Patients given long-term antibiotic prophylaxis at discharge had no differences in 6-month mortality compared with nonantibiotic patients, although antibiotic-treated patients had more infections at trial entry, with numbers too small for matching. DISCUSSION: Half of antibiotics at study entry were given to patients without an infection diagnosis which did not reduce the overall risk of HAI or improve mortality. This supports prompt de-escalation or discontinuation of antibiotics guided by culture sensitivities at 24-48 hours after commencement if no infection and the patient is improving.Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


Files in this item

Thumbnail
Name:
Evaluating the role of antibiotics ...
Size:
201.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record